N8 Medical Announces First-in-Human Use of its CeraShield™ Endotracheal Tube
CeraShield™ resorbable envelope targets prevention of bacterial and highly lethal fungal infections and reduction of surgical site infections of pacemaker implantations
New Publication regarding Ceragenin CSA-131’s Potent Efficacy against fungal pathogen Candida auris, a New Serious Global Health Threat
Plans to Initiate First-in-Human testing in First Quarter of 2018
CeraShield™ Coating Prevents Bacterial and Fungal Colonization, and Reduces Endotoxin
FDA Grants N8 Medical’s Request for Breakthrough Device Designation for its CeraShield™ Endotracheal Tube
A recent published study by Professor Robert Bucki and colleagues has shown that CSA-131 has broad spectrum antifungal activity and retains activity in various body fluids.